Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

Current and future applications of liquid biopsy in nonsmall cell lung cancer from early to advanced stages.

Guibert N, Pradines A, Favre G, Mazieres J.

Eur Respir Rev. 2020 Feb 12;29(155). pii: 190052. doi: 10.1183/16000617.0052-2019. Print 2020 Mar 31. Review.

2.

Targeted sequencing of plasma cell-free DNA to predict response to PD1 inhibitors in advanced non-small cell lung cancer.

Guibert N, Jones G, Beeler JF, Plagnol V, Morris C, Mourlanette J, Delaunay M, Keller L, Rouquette I, Favre G, Pradines A, Mazieres J.

Lung Cancer. 2019 Nov;137:1-6. doi: 10.1016/j.lungcan.2019.09.005. Epub 2019 Sep 6.

PMID:
31518912
3.

Early Circulating Tumour DNA Variations Predict Tumour Response in Melanoma Patients Treated with Immunotherapy.

Keller L, Guibert N, Casanova A, Brayer S, Farella M, Delaunay M, Gilhodes J, Martin E, Balagué G, Favre G, Pradines A, Meyer N.

Acta Derm Venereol. 2019 Feb 1;99(2):206-210. doi: 10.2340/00015555-3080.

4.

Cytoplasmic p27Kip1 promotes tumorigenesis via suppression of RhoB activity.

Calvayrac O, Nowosad A, Cabantous S, Lin LP, Figarol S, Jeannot P, Serres MP, Callot C, Perchey RT, Creff J, Taranchon-Clermont E, Rouquette I, Favre G, Pradines A, Manenti S, Mazieres J, Lee H, Besson A.

J Pathol. 2019 Jan;247(1):60-71. doi: 10.1002/path.5167. Epub 2018 Dec 11.

PMID:
30206932
5.

PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab.

Guibert N, Delaunay M, Lusque A, Boubekeur N, Rouquette I, Clermont E, Mourlanette J, Gouin S, Dormoy I, Favre G, Mazieres J, Pradines A.

Lung Cancer. 2018 Jun;120:108-112. doi: 10.1016/j.lungcan.2018.04.001. Epub 2018 Apr 3.

PMID:
29748004
6.

[The Ras-related GTPase RhoB, a relevant actor in the adaptive resistance to EGFR tyrosine kinase inhibitors in lung cancers].

Calvayrac O, Pradines A, Mazières J, Favre G.

Med Sci (Paris). 2018 Jan;34(1):12-14. doi: 10.1051/medsci/20183401003. Epub 2018 Jan 31. French. No abstract available.

7.

Circulating cell-free microRNAs as clinical cancer biomarkers.

Armand-Labit V, Pradines A.

Biomol Concepts. 2017 May 24;8(2):61-81. doi: 10.1515/bmc-2017-0002. Review.

PMID:
28448269
8.

Monitoring of KRAS-mutated ctDNA to discriminate pseudo-progression from true progression during anti-PD-1 treatment of lung adenocarcinoma.

Guibert N, Mazieres J, Delaunay M, Casanova A, Farella M, Keller L, Favre G, Pradines A.

Oncotarget. 2017 Jun 6;8(23):38056-38060. doi: 10.18632/oncotarget.16935.

9.

Molecular biomarkers for lung adenocarcinoma.

Calvayrac O, Pradines A, Pons E, Mazières J, Guibert N.

Eur Respir J. 2017 Apr 5;49(4). pii: 1601734. doi: 10.1183/13993003.01734-2016. Print 2017 Apr. Review.

10.

The RAS-related GTPase RHOB confers resistance to EGFR-tyrosine kinase inhibitors in non-small-cell lung cancer via an AKT-dependent mechanism.

Calvayrac O, Mazières J, Figarol S, Marty-Detraves C, Raymond-Letron I, Bousquet E, Farella M, Clermont-Taranchon E, Milia J, Rouquette I, Guibert N, Lusque A, Cadranel J, Mathiot N, Savina A, Pradines A, Favre G.

EMBO Mol Med. 2017 Feb;9(2):238-250. doi: 10.15252/emmm.201606646.

11.

International Interlaboratory Digital PCR Study Demonstrating High Reproducibility for the Measurement of a Rare Sequence Variant.

Whale AS, Devonshire AS, Karlin-Neumann G, Regan J, Javier L, Cowen S, Fernandez-Gonzalez A, Jones GM, Redshaw N, Beck J, Berger AW, Combaret V, Dahl Kjersgaard N, Davis L, Fina F, Forshew T, Fredslund Andersen R, Galbiati S, González Hernández Á, Haynes CA, Janku F, Lacave R, Lee J, Mistry V, Pender A, Pradines A, Proudhon C, Saal LH, Stieglitz E, Ulrich B, Foy CA, Parkes H, Tzonev S, Huggett JF.

Anal Chem. 2017 Feb 7;89(3):1724-1733. doi: 10.1021/acs.analchem.6b03980. Epub 2017 Jan 18.

PMID:
27935690
12.

RHOB expression controls the activity of serine/threonine protein phosphatase PP2A to modulate mesenchymal phenotype and invasion in non-small cell lung cancers.

Calvayrac O, Pradines A, Favre G.

Small GTPases. 2018 Jul 4;9(4):339-344. doi: 10.1080/21541248.2016.1234429. Epub 2016 Nov 1. Review.

13.

Monitoring KRAS mutations in circulating DNA and tumor cells using digital droplet PCR during treatment of KRAS-mutated lung adenocarcinoma.

Guibert N, Pradines A, Farella M, Casanova A, Gouin S, Keller L, Favre G, Mazieres J.

Lung Cancer. 2016 Oct;100:1-4. doi: 10.1016/j.lungcan.2016.07.021. Epub 2016 Jul 22.

PMID:
27597273
14.

Detection and Monitoring of the BRAF Mutation in Circulating Tumor Cells and Circulating Tumor DNA in BRAF-Mutated Lung Adenocarcinoma.

Guibert N, Pradines A, Casanova A, Farella M, Keller L, Soria JC, Favre G, Mazières J.

J Thorac Oncol. 2016 Sep;11(9):e109-12. doi: 10.1016/j.jtho.2016.05.001. Epub 2016 May 7. No abstract available.

15.

RhoB loss induces Rac1-dependent mesenchymal cell invasion in lung cells through PP2A inhibition.

Bousquet E, Calvayrac O, Mazières J, Lajoie-Mazenc I, Boubekeur N, Favre G, Pradines A.

Oncogene. 2016 Apr 7;35(14):1760-9. doi: 10.1038/onc.2015.240. Epub 2015 Jul 6.

PMID:
26148238
16.

The c-Jun/RHOB/AKT pathway confers resistance of BRAF-mutant melanoma cells to MAPK inhibitors.

Delmas A, Cherier J, Pohorecka M, Medale-Giamarchi C, Meyer N, Casanova A, Sordet O, Lamant L, Savina A, Pradines A, Favre G.

Oncotarget. 2015 Jun 20;6(17):15250-64.

17.

Identification of a Circulating MicroRNA Profile as a Biomarker of Metastatic Cutaneous Melanoma.

Armand-Labit V, Meyer N, Casanova A, Bonnabau H, Platzer V, Tournier E, Sansas B, Verdun S, Thouvenot B, Hilselberger B, Doncescu A, Lamant L, Lacroix-Triki M, Favre G, Pradines A.

Acta Derm Venereol. 2016 Jan;96(1):29-34. doi: 10.2340/00015555-2156.

18.

RhoB determines tumor aggressiveness in a murine EGFRL858R-induced adenocarcinoma model and is a potential prognostic biomarker for Lepidic lung cancer.

Calvayrac O, Pradines A, Raymond-Letron I, Rouquette I, Bousquet E, Lauwers-Cances V, Filleron T, Cadranel J, Beau-Faller M, Casanova A, Milia J, Favre G, Mazières J.

Clin Cancer Res. 2014 Dec 15;20(24):6541-50. doi: 10.1158/1078-0432.CCR-14-0506. Epub 2014 Oct 15.

19.

RhoB promotes cancer initiation by protecting keratinocytes from UVB-induced apoptosis but limits tumor aggressiveness.

Meyer N, Peyret-Lacombe A, Canguilhem B, Médale-Giamarchi C, Mamouni K, Cristini A, Monferran S, Lamant L, Filleron T, Pradines A, Sordet O, Favre G.

J Invest Dermatol. 2014 Jan;134(1):203-212. doi: 10.1038/jid.2013.278. Epub 2013 Jun 21.

20.

Loss of RhoB expression promotes migration and invasion of human bronchial cells via activation of AKT1.

Bousquet E, Mazières J, Privat M, Rizzati V, Casanova A, Ledoux A, Mery E, Couderc B, Favre G, Pradines A.

Cancer Res. 2009 Aug 1;69(15):6092-9. doi: 10.1158/0008-5472.CAN-08-4147. Epub 2009 Jul 14.

21.

Phosphorylation of RhoB by CK1 impedes actin stress fiber organization and epidermal growth factor receptor stabilization.

Tillement V, Lajoie-Mazenc I, Casanova A, Froment C, Penary M, Tovar D, Marquez R, Monsarrat B, Favre G, Pradines A.

Exp Cell Res. 2008 Sep 10;314(15):2811-21. doi: 10.1016/j.yexcr.2008.06.011. Epub 2008 Jun 18.

PMID:
18590726
22.

In vivo restoration of RhoB expression leads to ovarian tumor regression.

Couderc B, Pradines A, Rafii A, Golzio M, Deviers A, Allal C, Berg D, Penary M, Teissie J, Favre G.

Cancer Gene Ther. 2008 Jul;15(7):456-64. doi: 10.1038/cgt.2008.12. Epub 2008 Mar 14.

PMID:
18340357
23.

MAP1A light chain-2 interacts with GTP-RhoB to control epidermal growth factor (EGF)-dependent EGF receptor signaling.

Lajoie-Mazenc I, Tovar D, Penary M, Lortal B, Allart S, Favard C, Brihoum M, Pradines A, Favre G.

J Biol Chem. 2008 Feb 15;283(7):4155-64. Epub 2007 Dec 3.

24.

Epigenetic regulation of RhoB loss of expression in lung cancer.

Mazières J, Tovar D, He B, Nieto-Acosta J, Marty-Detraves C, Clanet C, Pradines A, Jablons D, Favre G.

BMC Cancer. 2007 Nov 30;7:220.

25.

Reversible inactivation of the transcriptional function of P53 protein by farnesylation.

Couderc B, Penary M, Tohfe M, Pradines A, Casteignau A, Berg D, Favre G.

BMC Biotechnol. 2006 May 29;6:26.

26.

Zoledronic acid treatment impairs protein geranyl-geranylation for biological effects in prostatic cells.

Goffinet M, Thoulouzan M, Pradines A, Lajoie-Mazenc I, Weinbaum C, Faye JC, Séronie-Vivien S.

BMC Cancer. 2006 Mar 15;6:60.

27.

RhoB protects human keratinocytes from UVB-induced apoptosis through epidermal growth factor receptor signaling.

Canguilhem B, Pradines A, Baudouin C, Boby C, Lajoie-Mazenc I, Charveron M, Favre G.

J Biol Chem. 2005 Dec 30;280(52):43257-63. Epub 2005 Nov 8.

28.

Selective inhibition of HER2 inhibits AKT signal transduction and prolongs disease-free survival in a micrometastasis model of ovarian carcinoma.

Delord JP, Allal C, Canal M, Mery E, Rochaix P, Hennebelle I, Pradines A, Chatelut E, Bugat R, Guichard S, Canal P.

Ann Oncol. 2005 Dec;16(12):1889-97. Epub 2005 Oct 11.

29.

Screening approach for chiral separation of pharmaceuticals. Part III. Supercritical fluid chromatography for analysis and purification in drug discovery.

Maftouh M, Granier-Loyaux C, Chavana E, Marini J, Pradines A, Heyden YV, Picard C.

J Chromatogr A. 2005 Sep 23;1088(1-2):67-81.

PMID:
16130734
30.

Farnesylated RhoB inhibits radiation-induced mitotic cell death and controls radiation-induced centrosome overduplication.

Milia J, Teyssier F, Dalenc F, Ader I, Delmas C, Pradines A, Lajoie-Mazenc I, Baron R, Bonnet J, Cohen-Jonathan E, Favre G, Toulas C.

Cell Death Differ. 2005 May;12(5):492-501.

31.

Geranylgeranylated, but not farnesylated, RhoB suppresses Ras transformation of NIH-3T3 cells.

Mazières J, Tillement V, Allal C, Clanet C, Bobin L, Chen Z, Sebti SM, Favre G, Pradines A.

Exp Cell Res. 2005 Apr 1;304(2):354-64. Epub 2004 Dec 28.

PMID:
15748883
32.

Loss of RhoB expression in human lung cancer progression.

Mazieres J, Antonia T, Daste G, Muro-Cacho C, Berchery D, Tillement V, Pradines A, Sebti S, Favre G.

Clin Cancer Res. 2004 Apr 15;10(8):2742-50.

33.

Perspectives on farnesyl transferase inhibitors in cancer therapy.

Mazieres J, Pradines A, Favre G.

Cancer Lett. 2004 Apr 8;206(2):159-67. Review.

PMID:
15013521
34.

[Farnesyl transferase inhibitors: one target may be found in another].

Mazières J, Pradines A, Favre G.

Med Sci (Paris). 2003 Feb;19(2):211-6. Review. French.

35.

Farnesylated RhoB prevents cell cycle arrest and actin cytoskeleton disruption caused by the geranylgeranyltransferase I inhibitor GGTI-298.

Allal C, Pradines A, Hamilton AD, Sebti SM, Favre G.

Cell Cycle. 2002 Nov-Dec;1(6):430-7.

PMID:
12548020
36.

Inhibition of human tumor cell growth in vivo by an orally bioavailable inhibitor of human farnesyltransferase, BIM-46228.

Prevost GP, Pradines A, Brezak MC, Lonchampt MO, Viossat I, Ader I, Toulas C, Kasprzyk P, Gordon T, Favre G, Morgan B.

Int J Cancer. 2001 Mar 1;91(5):718-22.

37.

RhoB prenylation is driven by the three carboxyl-terminal amino acids of the protein: evidenced in vivo by an anti-farnesyl cysteine antibody.

Baron R, Fourcade E, Lajoie-Mazenc I, Allal C, Couderc B, Barbaras R, Favre G, Faye JC, Pradines A.

Proc Natl Acad Sci U S A. 2000 Oct 10;97(21):11626-31.

38.

RhoA prenylation is required for promotion of cell growth and transformation and cytoskeleton organization but not for induction of serum response element transcription.

Allal C, Favre G, Couderc B, Salicio S, Sixou S, Hamilton AD, Sebti SM, Lajoie-Mazenc I, Pradines A.

J Biol Chem. 2000 Oct 6;275(40):31001-8.

39.

Both farnesylated and geranylgeranylated RhoB inhibit malignant transformation and suppress human tumor growth in nude mice.

Chen Z, Sun J, Pradines A, Favre G, Adnane J, Sebti SM.

J Biol Chem. 2000 Jun 16;275(24):17974-8.

40.

Inhibition of human tumor cell growth in vitro and in vivo by a specific inhibitor of human farnesyltransferase: BIM-46068.

Prevost GP, Pradines A, Viossat I, Brezak MC, Miquel K, Lonchampt MO, Kasprzyk P, Favre G, Pignol B, Le Breton C, Dong J, Morgan B.

Int J Cancer. 1999 Oct 8;83(2):283-7.

41.

Epidermal growth factor stimulates 3-hydroxy-3-methylglutaryl-coenzyme A reductase expression via the ErbB-2 pathway in human breast adenocarcinoma cells.

Asslan R, Pradines A, Pratx C, Allal C, Favre G, Le Gaillard F.

Biochem Biophys Res Commun. 1999 Jul 14;260(3):699-706.

PMID:
10403829
43.
44.

GGTI-298 induces G0-G1 block and apoptosis whereas FTI-277 causes G2-M enrichment in A549 cells.

Miquel K, Pradines A, Sun J, Qian Y, Hamilton AD, Sebti SM, Favre G.

Cancer Res. 1997 May 15;57(10):1846-50.

45.

Farnesol and geranylgeraniol induce actin cytoskeleton disorganization and apoptosis in A549 lung adenocarcinoma cells.

Miquel K, Pradines A, Favre G.

Biochem Biophys Res Commun. 1996 Aug 23;225(3):869-76.

PMID:
8780704
46.

Reversion of transformed phenotype of human adenocarcinoma A549 cells by expression of 3-hydroxy-3-methylglutaryl coenzyme A reductase complementary DNA.

Seronie-Vivien S, Pradines A, Couderc B, Clamagirand C, Berg D, Soula G, Favre G.

Cell Growth Differ. 1995 Nov;6(11):1415-23.

47.

Evidence for nerve growth factor-potentiating activities of the nonpeptidic compound SR 57746A in PC12 cells.

Pradines A, Magazin M, Schiltz P, Le Fur G, Caput D, Ferrara P.

J Neurochem. 1995 May;64(5):1954-64.

PMID:
7722483

Supplemental Content

Loading ...
Support Center